---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-009903"
form_type: "8-K"
ticker: "FBIO"
cik: "0001429260"
company_name: "Fortress Biotech, Inc."
filed_at: "2024-07-19T23:59:59+00:00"
generated_at: "2026-05-31T18:59:45.123744+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Fortress Biotech's Urica sells gout drug dotinurad to Crystalys for 35% equity and 3% royalty

## Summary
- Urica sold its URAT1 inhibitor dotinurad (gout treatment) and related IP to Crystalys Therapeutics.
- Urica received 35% of Crystalys' outstanding equity; cannot be diluted below 15% until Crystalys raises $150M in equity.
- Urica gets a securitized 3% royalty on future net sales of dotinurad plus nominal cost reimbursements.
- Urica has the right to appoint one director and one board observer to Crystalys' board.
- Crystalys must use commercially reasonable efforts to develop and commercialize dotinurad.

## SEC filing metadata
- accession: 0001558370-24-009903
- form_type: 8-K
- ticker: FBIO
- cik: 0001429260
- company_name: Fortress Biotech, Inc.
- filed_at: 2024-07-19T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1429260/000155837024009903/0001558370-24-009903-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1429260/000155837024009903/fbio-20240715x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-009903
- JSON: https://secwatch.observer/filing/0001558370-24-009903.json
- Plain text: https://secwatch.observer/filing/0001558370-24-009903.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.